C4XD provides update on diabetes & inflammation compounds
23 September 2015 | By Victoria White
C4XD expects to progress its type 2 diabetes and inflammation programmes into in vivo proof-of-principle testing in the next few months...
List view / Grid view
23 September 2015 | By Victoria White
C4XD expects to progress its type 2 diabetes and inflammation programmes into in vivo proof-of-principle testing in the next few months...
23 September 2015 | By Victoria White
Inquiro gathers all unstructured data – from R&D to preclinical data – and allows researchers to organise and interconnect such data, facilitating large-scale collaborations among geographically distant research teams...
23 September 2015 | By Victoria White
NanoBio’s intranasal nanoemulsion adjuvanted genital herpes vaccine demonstrated efficacy in studies conducted in prophylactic and therapeutic models...
22 September 2015 | By Victoria White
This work builds on previous successful collaborations between Zedira and Cardiff University in the arena of the autoantibody response in gluten-related disorders...
22 September 2015 | By Victoria White
The companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets...
22 September 2015 | By Victoria White
The companies have applied a crowdsourcing approach to establish a research team who will endeavour to identify new approaches for the treatment of patients with COPD...
21 September 2015 | By Victoria White
DARPA is to provide the additional $24 million after Inovio successfully completed certain preclinical and clinical development milestones relating to the Ebola treatment programme...
21 September 2015 | By Victoria White
The data highlights that BGB324 used in combination with immune checkpoint inhibitors in mouse carcinoma models showed enhanced tumour clearance compared with checkpoint inhibition alone...
21 September 2015 | By Victoria White
Dr Wood's expertise and experience to support Nuevolution in developing its pipeline in oncology, inflammation and immuno-oncology...
21 September 2015 | By Victoria White
Appreciating the importance of the US biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc...
17 September 2015 | By Vicky White
By identifying ERManI as the target that slows the spread of HIV-1, researchers have revealed a target in which future therapies can be developed...
17 September 2015 | By Victoria White
The researchers also determined that the level of biomarkers associated with ovarian cancer does not simply increase or decrease over the course of the disease...
17 September 2015 | By Victoria White
The new technique could be used to explore genetic mechanisms of resistance in the field of infectious disease and lead to new therapies...
17 September 2015 | By Victoria White
The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb bispecific technology platform...
17 September 2015 | By Victoria White
Piramal has launched a series of green chemistry initiatives and is asking all its partners to evaluate the greenness of the chemical pathways they are using...